IQE PLC
04 September 2007
IQE plc ('the Company')
DIRECTORS' DEALINGS
IQE plc announces that 68,043 new ordinary shares have been issued to Gambit
Corporate Finance in settlement of the fees of the Non-Executive Chairman
Godfrey Ainsworth for April to June 2007. Following this issue the total number
of ordinary shares in issue is 430,830,211. The shares will be allotted and
issued as detailed below:
Shareholder name Shares issued Average price
Gambit Corporate Finance 68,043 15.11p
Following this issue, the Non-Executive Chairman of the Company Dr Godfrey
Ainsworth's total beneficial interest in the Company is 3,412,731 shares
representing 0.79% of the issued share capital. Dr Godfrey Ainsworth holds this
interest in IQE plc as an equity partner of Gambit Corporate Finance in respect
of 2,391,432 shares and as sole beneficial owner of the balance of 1,021,299
shares.
Application has been made to the London Stock Exchange for the shares to be
admitted to AIM.
Contacts
IQE plc +44(0) 29 2083 9400
Dr Drew Nelson, President & CEO
Chris Meadows, Investor Relations
Noble & Company Limited +44(0) 20 7763 2200
John Llewellyn-Lloyd
This information is provided by RNS
The company news service from the London Stock Exchange
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.